Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on ...

In a report released today, Judah Frommer from Morgan Stanley maintained a Hold rating on Galapagos (GLPG – Research Report), with a price ...

Galapagos NV (NASDAQ:GLPG – Get Free Report) has received an average recommendation of “Reduce” from the eight research firms ...

Belgium-based biotech company Galapagos NV's (GLPG) U.S.-listed shares rose over 4% in Wednesday's premarket after it announced a significant restructuring plan, including a spin-off into two ...

Fintel reports that on January 23, 2025, Barclays downgraded their outlook for Galapagos NV - Depositary Receipt () (NasdaqGS:GLPG) from Equal-Weight to Underweight. Analyst Price Forecast Suggests 48 ...

Galapagos (0JXZ – Research Report) received a Sell rating and a €22.00 price target from Barclays analyst Emily Field today. The company’s ...

Galapagos NV has a twelve month low of $23.45 and a twelve month high of $40.34. The business’s 50-day moving average price is $26.55 and its two-hundred day moving average price is $27.41 ...

Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at ...

MECHELEN, Belgium – January 8, 2025 – 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) (“Galapagos” or the ...

Will further expand Galapagos’ manufacturing network in the U.S. for improved patient experience.

Galapagos NV (NASDAQ:GLPG) is under modest pressure premarket, down 6% on increased volume on the heels of promising results from Vertex Pharmaceuticals' (NASDAQ:VRTX) triple... BySeeking Alpha ...

Catalent has entered a strategic partnership with Galapagos to facilitate decentralised manufacturing for the latter’s ...